The test, developed by EDP Biotech, will initially be introduced to the 30 member states of the European Economic Area.
ColoMarker has been clinically tested in the United States. It has demonstrated 97 percent sensitivity, 86 percent specificity for colorectal cancer and a 48 percent detection rate of adenomatous polyps.
More articles on gastroenterology:
Are current endoscopy cleaning protocols enough?
Hudson Valley Hospital Center adds 2 gastroenterologists
HCV drug Sovaldi sales on the decline
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
